- Details
- Description
-
Packaging Size10ml/bottel
-
Strength100mg
-
CompositonPenpulimab
-
TreatmentHodgkin's lymphoma, Nasopharyngeal cancer, Non-small cell lung cancer (NSCLC), and Solid tumors.
-
FormInjection
-
Brand安尼可 (Anike)
-
Quantity Unit100mg(10ml)/Bottle/Box
-
ManufacturerChia Tai Tianqing,china
About Penpulimab
Penpulimab is an IgG1 monoclonal antibody that's designed to eliminate Fcγ receptor binding and Fc-mediated effector functions. This is intended to reduce immune-related adverse events (irAEs) while maintaining efficacy.
- Penpulimab sold under the brand name 安尼可® (Anike) in china.
In August 2021, penpulimab received its first approval in China for the treatment of adult patients with relapsed or refractory classic Hodgkin's lymphoma who have undergone at least second-line chemotherapy. Penpulimab is under regulatory review for nasopharyngeal cancer and NSCLC in China. Clinical studies of penpulimab are underway for various cancers in China and Australia. This article summarizes the milestones in the development of penpulimab leading to this first approval for relapsed or refractory classic Hodgkin's lymphoma.
